Chengdu Easton Biopharmaceuticals Hits Day Low Amid Price Pressure at CNY 44.91

Chengdu Easton Biopharmaceuticals Co., Ltd. experienced a notable decline today, with the stock dropping by 5.28% to reach an intraday low of CNY 44.91. This performance contrasts sharply with the China Shanghai Composite, which saw a slight increase of 0.04% on the same day. Over the past week, Chengdu Easton has faced a more significant downturn, with a decline of 8.29%. The stock's performance over the past month has also been challenging, showing a decrease of 16.17%. Year-to-date, the stock has fallen by 25.98%, while its performance over the last year reflects a decline of 28.05%. In comparison, the China Shanghai Composite has shown a positive return of 3.56% over the same period. Despite the recent downturn, the company maintains a market capitalization of CNY 8,700 million and a price-to-earnings ratio of 31.00. The firm has reported a return on equity of 7.99% and a dividend yield of 0.68%. However, the long-term growth metrics indicate a slower pace, with net sales growing at an annual rate of 8.13% over the last five years.